Close Menu

This article was originally published Feb. 6.

Following the burst of next-generation sequencing technologies onto the scene, Sanger sequencing may have slipped out of the limelight, but it is still laboring away in a few laboratories.

Robert Lyons, the director of the University of Michigan DNA Sequencing Core, said that while he has seen a decline in demand for Sanger sequencing, it has not been large. "The business has gone down about 10 percent," he said. "We still do 300,000 samples or 300,000 reactions a year here."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.